Replimune Group, Inc. (NASDAQ:REPL) Shares Bought by MetLife Investment Management LLC

MetLife Investment Management LLC grew its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL) by 21.5% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 35,134 shares of the company’s stock after purchasing an additional 6,216 shares during the period. MetLife Investment Management LLC’s holdings in Replimune Group were worth $385,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. LMR Partners LLP grew its position in Replimune Group by 145.8% in the third quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock worth $904,000 after buying an additional 48,920 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Replimune Group by 575.1% during the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after acquiring an additional 2,656,173 shares in the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of Replimune Group by 282.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock worth $650,000 after acquiring an additional 53,313 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Replimune Group by 63.2% during the second quarter. Acadian Asset Management LLC now owns 185,516 shares of the company’s stock worth $1,668,000 after purchasing an additional 71,867 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in shares of Replimune Group during the third quarter valued at $251,000. 92.53% of the stock is currently owned by institutional investors.

Insider Activity at Replimune Group

In other news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 8.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have issued reports on REPL. Roth Mkm assumed coverage on Replimune Group in a report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $17.00 price target on shares of Replimune Group in a research report on Friday, November 22nd. BMO Capital Markets lifted their price objective on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research report on Friday, November 22nd. Jefferies Financial Group increased their target price on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. Finally, Roth Capital upgraded Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $17.29.

Replimune Group Price Performance

NASDAQ:REPL opened at $13.08 on Monday. The company has a market capitalization of $894.89 million, a price-to-earnings ratio of -4.29 and a beta of 1.26. The company has a 50-day moving average of $12.10 and a 200-day moving average of $10.27. Replimune Group, Inc. has a 52 week low of $4.92 and a 52 week high of $17.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.07. As a group, equities research analysts anticipate that Replimune Group, Inc. will post -2.99 earnings per share for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.